

Nathalie L Albert

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7637872/publications.pdf>

Version: 2024-02-01

127
papers

4,585
citations

136950

32
h-index

118850

62
g-index

133
all docs

133
docs citations

133
times ranked

4517
citing authors

#	ARTICLE	IF	CITATIONS
1	68Ga-EMP-100 PET/CTâ€”a novel ligand for visualizing c-MET expression in metastatic renal cell carcinomaâ€”first in-human biodistribution and imaging results. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1711-1720.	6.4	15
2	Case 32: Suspected Recurrence of Brain Metastasis After Radiotherapy. , 2022, , 159-161.		0
3	Case 25: Primary Diagnosis of an Isocitrate Dehydrogenase (IDH) Wild-Type Glioma. , 2022, , 125-128.		0
4	Impact of Partial Volume Correction on [18F]GE-180 PET Quantification in Subcortical Brain Regions of Patients with Corticobasal Syndrome. <i>Brain Sciences</i> , 2022, 12, 204.	2.3	2
5	Differential Spatial Distribution of TSPO or Amino Acid PET Signal and MRI Contrast Enhancement in Gliomas. <i>Cancers</i> , 2022, 14, 53.	3.7	12
6	Detection of Splenic Tissue Using 99mTc-Labelled Denatured Red Blood Cells Scintigraphyâ€”A Quantitative Single Center Analysis. <i>Diagnostics</i> , 2022, 12, 486.	2.6	3
7	Highlights of the 34th EANM Annual Congress 2021, 2nd virtual edition: â€œFROM HAMBURG WITH LOVEâ€” <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1435-1441.	6.4	1
8	Longitudinal [18F]GE-180 PET Imaging Facilitates In Vivo Monitoring of TSPO Expression in the GL261 Glioblastoma Mouse Model. <i>Biomedicines</i> , 2022, 10, 738.	3.2	8
9	Diagnostic Yield and Complication Rate of Stereotactic Biopsies in Precision Medicine of Gliomas. <i>Frontiers in Neurology</i> , 2022, 13, 822362.	2.4	18
10	Feasibility of [68Ga]Ga-FAPI-46 PET/CT for detection of nodal and hematogenous spread in high-grade urothelial carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3571-3580.	6.4	12
11	EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 632-651.	6.4	82
12	Total Tumor Volume on 18F-PSMA-1007 PET as Additional Imaging Biomarker in mCRPC Patients Undergoing PSMA-Targeted Alpha Therapy with 225Ac-PSMA-I&T. <i>Biomedicines</i> , 2022, 10, 946.	3.2	6
13	Joint EANM/SIOPE/RAPNO practice guidelines/SNMMI procedure standards for imaging of paediatric gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3852-3869.	6.4	14
14	Increased TSPO PET signal after radiochemotherapy in IDH-wildtype gliomaâ€”indicator for treatment-induced immune activation?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 4282-4283.	6.4	7
15	Investigational PET tracers in neuro-oncologyâ€”Whatâ€™s on the horizon? A report of the PET/RANO group. <i>Neuro-Oncology</i> , 2022, 24, 1815-1826.	1.2	14
16	Simpson Grade Revisited â€” Intraoperative Estimation of the Extent of Resection in Meningiomas Versus Postoperative Somatostatin Receptor Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging. <i>Neurosurgery</i> , 2021, 88, 140-146.	1.1	27
17	Clinical impact of follicular oncocytic (HÃ¼rtle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 449-460.	6.4	14
18	In Vivo Assessment of Neuroinflammation in <sc>4â€”Repeat</sc> Tauopathies. <i>Movement Disorders</i> , 2021, 36, 883-894.	3.9	37

#	ARTICLE	IF	CITATIONS
19	The diagnostic challenge of coexistent sarcoidosis and thyroid cancer – a retrospective study. <i>BMC Cancer</i> , 2021, 21, 139.	2.6	7
20	Detection Gap of Right-Asymmetric Neuronal Degeneration by CERAD Test Battery in Alzheimer’s Disease. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 611595.	3.4	2
21	TSPO PET imaging of natalizumab-associated progressive multifocal leukoencephalopathy. <i>Brain</i> , 2021, 144, 2683-2695.	7.6	13
22	PSMA Expression in Glioblastoma as a Basis for Theranostic Approaches: A Retrospective, Correlational Panel Study Including Immunohistochemistry, Clinical Parameters and PET Imaging. <i>Frontiers in Oncology</i> , 2021, 11, 646387.	2.8	35
23	Use of PET Imaging in Neuro-Oncological Surgery. <i>Cancers</i> , 2021, 13, 2093.	3.7	23
24	TERT-Promoter Mutational Status in Glioblastoma – Is There an Association With Amino Acid Uptake on Dynamic 18F-FET PET?. <i>Frontiers in Oncology</i> , 2021, 11, 645316.	2.8	4
25	Impact of TSPO Receptor Polymorphism on [18F]GE-180 Binding in Healthy Brain and Pseudo-Reference Regions of Neurooncological and Neurodegenerative Disorders. <i>Life</i> , 2021, 11, 484.	2.4	11
26	Feasibility of Different Tumor Delineation Approaches for 18F-PSMA-1007 PET/CT Imaging in Prostate Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 663631.	2.8	7
27	Breast Cancer Metastasis Mimicking Meningioma in 68Ga-DOTATOC PET/CT. <i>Clinical Nuclear Medicine</i> , 2021, Publish Ahead of Print, 922-923.	1.3	3
28	18F-FET PET Uptake Characteristics of Long-Term IDH-Wildtype Diffuse Glioma Survivors. <i>Cancers</i> , 2021, 13, 3163.	3.7	5
29	Value of PET imaging for radiation therapy. <i>Nuklearmedizin - NuclearMedicine</i> , 2021, 60, 326-343.	0.7	2
30	The approval of a disease-modifying treatment for Alzheimer’s disease: impact and consequences for the nuclear medicine community. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3033-3036.	6.4	6
31	Value of PET imaging for radiation therapy. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 1-23.	2.0	16
32	Multimodal therapy of cavernous sinus meningioma: impact of surgery and 68Ga-DOTATATE PET-guided radiation therapy on tumor control and functional outcome. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab114.	0.7	2
33	Risk Stratification Using 18F-FDG PET/CT and Artificial Neural Networks in Head and Neck Cancer Patients Undergoing Radiotherapy. <i>Diagnostics</i> , 2021, 11, 1581.	2.6	5
34	Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [18F]FET PET radiomics. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 4415-4425.	6.4	29
35	Photopenic Defects in Gliomas With Amino-Acid PET and Relative Prognostic Value. <i>Clinical Nuclear Medicine</i> , 2021, 46, e36-e37.	1.3	11
36	PSMA PET Imaging in Glioblastoma: A Preclinical Evaluation and Theranostic Outlook. <i>Frontiers in Oncology</i> , 2021, 11, 774017.	2.8	10

#	ARTICLE	IF	CITATIONS
37	Associations between sex, body mass index, and the individual microglial response in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0
38	L-type amino acid transporter (LAT) 1 expression in 18F-FET-negative gliomas. <i>EJNMMI Research</i> , 2021, 11, 124.	2.5	13
39	Margin reduction in radiotherapy for glioblastoma through 18F-fluoroethyltyrosine PET? A recurrence pattern analysis. <i>Radiotherapy and Oncology</i> , 2020, 145, 49-55.	0.6	23
40	Longitudinal TSPO expression in tau transgenic P301S mice predicts increased tau accumulation and deteriorated spatial learning. <i>Journal of Neuroinflammation</i> , 2020, 17, 208.	7.2	19
41	18F-FDG PET/CT for Response Assessment in Pediatric Sebaceous Carcinoma of the Parotid Gland. <i>Diagnostics</i> , 2020, 10, 908.	2.6	1
42	COVID-19 and the brain: impact on nuclear medicine in neurology. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2487-2492.	6.4	18
43	In response to: Anatomy of 18F-GE180, a failed radioligand for the TSPO protein. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2237-2241.	6.4	9
44	Resting-state fMRI detects alterations in whole brain connectivity related to tumor biology in glioma patients. <i>Neuro-Oncology</i> , 2020, 22, 1388-1398.	1.2	60
45	Clinical value of [18F]FDG-PET/CT and 3D-black-blood 3T-MRI for the diagnosis of large vessel vasculitis and single-organ vasculitis of the aorta. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 194-202.	0.7	6
46	Metabolic Imaging of Brain Metastasis. , 2020, , 159-171.		0
47	Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas. <i>Neuro-Oncology</i> , 2019, 21, 274-284.	1.2	30
48	Neuronal injury biomarkers for assessment of the individual cognitive reserve in clinically suspected Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 24, 101949.	2.7	14
49	Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic 18F-FET PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2581-2589.	6.4	34
50	Long-term outcome of rare oncocyctic papillary (Hürthle cell) thyroid carcinoma following (adjuvant) initial radioiodine therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 2526-2535.	6.4	14
51	Current status of PET imaging in neuro-oncology. <i>Neuro-Oncology Advances</i> , 2019, 1, vdz010.	0.7	78
52	Longitudinal PET Monitoring of Amyloidosis and Microglial Activation in a Second-Generation Amyloid- β Mouse Model. <i>Journal of Nuclear Medicine</i> , 2019, 60, 1787-1793.	5.0	41
53	Report of first recurrent glioma patients examined with PET-MRI prior to re-irradiation. <i>PLoS ONE</i> , 2019, 14, e0216111.	2.5	7
54	Comment on "Hypometabolic gliomas on FET-PET" is there an inverted U-curve for survival? <i>Neuro-Oncology</i> , 2019, 21, 1612-1613.	1.2	9

#	ARTICLE	IF	CITATIONS
55	Imaging of Central Nervous System Tumors. , 2019, , 111-142.		0
56	Teaching NeuroImages: Advanced imaging of neurosarcoidosis with ⁶⁸ Ga-DOTATATE PET/CT. Neurology, 2019, 92, e2512-e2513.	1.1	4
57	Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET: clinical relevance in glioma patients. Neuro-Oncology, 2019, 21, 1331-1338.	1.2	31
58	In response to: The validity of 18F-GE180 as a TSPO imaging agent. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1208-1211.	6.4	19
59	Identification of Distant Metastases From Recurrent Gliosarcoma Using Whole-Body 18F-FDG PET/CT. Clinical Nuclear Medicine, 2019, 44, 923-924.	1.3	2
60	Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning. European Journal of Cancer, 2019, 107, 15-27.	2.8	30
61	PET imaging in patients with brain metastasis—report of the RANO/PET group. Neuro-Oncology, 2019, 21, 585-595.	1.2	139
62	Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 540-557.	6.4	348
63	Comparison of 18F-GE-180 and dynamic 18F-FET PET in high grade glioma: a double-tracer pilot study. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 580-590.	6.4	52
64	TSPO PET with [18F]GE-180 sensitively detects focal neuroinflammation in patients with relapsing-remitting multiple sclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1423-1431.	6.4	53
65	Combined [18F]-Fluoroethylcholine PET/CT and 99mTc-Macroaggregated Albumin SPECT/CT Predict Survival in Patients With Intermediate-Stage Hepatocellular Carcinoma. Clinical Nuclear Medicine, 2018, 43, 477-481.	1.3	2
66	Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma. Neuro-Oncology, 2018, 20, 279-288.	1.2	71
67	Coupling between physiological TSPO expression in brain and myocardium allows stabilization of late-phase cerebral [18F]GE180 PET quantification. NeuroImage, 2018, 165, 83-91.	4.2	27
68	Characterization of Diffuse Gliomas With Histone H3-G34 Mutation by MRI and Dynamic 18F-FET PET. Clinical Nuclear Medicine, 2018, 43, 895-898.	1.3	33
69	Role of amino-tracer PET for decision-making in neuro-oncology. Current Opinion in Neurology, 2018, 31, 720-726.	3.6	8
70	MNGI-35. SIMPSON GRADING REVISITED: SURGEONS ESTIMATION OF MENINGIOMA REMOVAL VS. POSTOPERATIVE 68GA-DOTATATE PET/CT. Neuro-Oncology, 2018, 20, vi156-vi156.	1.2	0
71	NIMG-41. NON-INVASIVE DETECTION OF IDH-WILDTYPE GENOTYPE IN GLIOMAS USING DYNAMIC 18F-FET-PET. Neuro-Oncology, 2018, 20, vi185-vi185.	1.2	0
72	Voxel-wise analysis of dynamic 18F-FET PET: a novel approach for non-invasive glioma characterisation. EJNMMI Research, 2018, 8, 91.	2.5	20

#	ARTICLE	IF	CITATIONS
73	Neurosarcoidosis Mimics High-Grade Glioma in Dynamic 18F-FET PET Due to LAT Expression. <i>Clinical Nuclear Medicine</i> , 2018, 43, 840-841.	1.3	7
74	Imaging microglial activation in tacrolimus-associated CNS vasculitis with translocator protein PET. <i>Neurology</i> , 2018, 91, 936-937.	1.1	6
75	Microglial response to increasing amyloid load saturates with aging: a longitudinal dual tracer in vivo ^{18}F PET-study. <i>Journal of Neuroinflammation</i> , 2018, 15, 307.	7.2	40
76	The role of amino-acid PET in the light of the new WHO classification 2016 for brain tumors. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 62, 267-271.	0.7	12
77	IgLON5: A case with predominant cerebellar tau deposits and leptomeningeal inflammation. <i>Neurology</i> , 2018, 91, 180-182.	1.1	23
78	18F-FET-PET as a biomarker for therapy response in non-contrast enhancing glioma following chemotherapy. <i>Journal of Neuro-Oncology</i> , 2018, 139, 721-730.	2.9	28
79	Recurrence pattern analysis after ^{68}Ga -DOTATATE-PET/CT -planned radiotherapy of high-grade meningiomas. <i>Radiation Oncology</i> , 2018, 13, 110.	2.7	16
80	Clinical Routine FDG-PET Imaging of Suspected Progressive Supranuclear Palsy and Corticobasal Degeneration: A Gatekeeper for Subsequent Tau-PET Imaging?. <i>Frontiers in Neurology</i> , 2018, 9, 483.	2.4	21
81	Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1573-1584.	6.4	18
82	Detection of Cerebrospinal Fluid Dissemination of Recurrent Glioblastoma Using TSPO-PET With 18F-GE-180. <i>Clinical Nuclear Medicine</i> , 2018, 43, 518-519.	1.3	18
83	Data on specificity of ^{18}F GE180 uptake for TSPO expression in rodent brain and myocardium. <i>Data in Brief</i> , 2018, 19, 331-336.	1.0	4
84	Comment on Hatzoglou et al: Dynamic contrast-enhanced MRI perfusion versus ^{18}F FDG PET/CT in differentiating brain tumor progression from radiation injury. <i>Neuro-Oncology</i> , 2017, 19, now283.	1.2	0
85	18F-FET PET prior to recurrent high-grade glioma re-irradiation—additional prognostic value of dynamic time-to-peak analysis and early static summation images?. <i>Journal of Neuro-Oncology</i> , 2017, 132, 277-286.	2.9	21
86	Identification of brain regions predicting epileptogenesis by serial ^{18}F GE-180 positron emission tomography imaging of neuroinflammation in a rat model of temporal lobe epilepsy. <i>NeuroImage: Clinical</i> , 2017, 15, 35-44.	2.7	22
87	Radiomic Analysis Reveals Prognostic Information in T1-Weighted Baseline Magnetic Resonance Imaging in Patients With Glioblastoma. <i>Investigative Radiology</i> , 2017, 52, 360-366.	6.2	96
88	Improved Detection of Transosseous Meningiomas Using ^{68}Ga -DOTATATE PET/CT Compared with Contrast-Enhanced MRI. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1580-1587.	5.0	81
89	PET imaging in patients with meningioma—report of the RANO/PET Group. <i>Neuro-Oncology</i> , 2017, 19, 1576-1587.	1.2	157
90	K27M midline gliomas display malignant progression by imaging and histology. <i>Neuropathology and Applied Neurobiology</i> , 2017, 43, 458-462.	3.2	9

#	ARTICLE	IF	CITATIONS
91	The endothelial prostate-specific membrane antigen is highly expressed in gliosarcoma and visualized by [68Ga]-PSMA-11 PET: a theranostic outlook for brain tumor patients?. <i>Neuro-Oncology</i> , 2017, 19, 1698-1699.	1.2	19
92	TSPO PET for glioma imaging using the novel ligand 18F-GE-180: first results in patients with glioblastoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 2230-2238.	6.4	91
93	Time Courses of Cortical Glucose Metabolism and Microglial Activity Across the Life Span of Wild-Type Mice: A PET Study. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1984-1990.	5.0	37
94	Towards standardization of 18F-FET PET imaging: do we need a consistent method of background activity assessment?. <i>EJNMMI Research</i> , 2017, 7, 48.	2.5	76
95	[18F]FDG PET accurately differentiates infected and non-infected non-unions after fracture fixation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 432-440.	6.4	20
96	TSPO imaging using the novel PET ligand [18F]GE-180: quantification approaches in patients with multiple sclerosis. <i>EJNMMI Research</i> , 2017, 7, 89.	2.5	55
97	Increase of TREM2 during Aging of an Alzheimer's Disease Mouse Model Is Paralleled by Microglial Activation and Amyloidosis. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 8.	3.4	60
98	In Vivo Imaging of Glial Activation after Unilateral Labyrinthectomy in the Rat: A [18F]GE180-PET Study. <i>Frontiers in Neurology</i> , 2017, 8, 665.	2.4	15
99	O-(2-[18F]fluoroethyl)-l-tyrosine PET in gliomas: influence of data processing in different centres. <i>EJNMMI Research</i> , 2017, 7, 64.	2.5	14
100	Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy. <i>Oncotarget</i> , 2017, 8, 44131-44140.	1.8	16
101	18F-FET PET Uptake Characteristics in Patients with Newly Diagnosed and Untreated Brain Metastasis. <i>Journal of Nuclear Medicine</i> , 2017, 58, 584-589.	5.0	36
102	Monitoring of Tumor Growth with [18F]-FET PET in a Mouse Model of Glioblastoma: SUV Measurements and Volumetric Approaches. <i>Frontiers in Neuroscience</i> , 2016, 10, 260.	2.8	13
103	Letter to the Editor: "Comparing the Volume of Brain Metastases in F-18-FET-PET and MRI". <i>World Neurosurgery</i> , 2016, 89, 722.	1.3	1
104	Serial ¹⁸ F-FET PET Imaging of Primarily ¹⁸ F-FET "Negative" Glioma: Does It Make Sense?. <i>Journal of Nuclear Medicine</i> , 2016, 57, 1177-1182.	5.0	56
105	Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. <i>Neuro-Oncology</i> , 2016, 18, 1199-1208.	1.2	566
106	Somatostatin-receptor-targeted radionuclide therapy for progressive meningioma: benefit linked to ⁶⁸ Ga-DOTATATE/TOC uptake. <i>Neuro-Oncology</i> , 2016, 18, now060.	1.2	79
107	The role of diffusion-weighted MRI in assessment of inflammatory bowel disease. <i>Abdominal Radiology</i> , 2016, 41, 1484-1494.	2.1	8
108	Occupancy of pramipexole (Sifrol) at cerebral dopamine D2/3 receptors in Parkinson's disease patients. <i>NeuroImage: Clinical</i> , 2016, 12, 41-46.	2.7	14

#	ARTICLE	IF	CITATIONS
109	Suspected recurrence of brain metastases after focused high dose radiotherapy: can [18F]FET- PET overcome diagnostic uncertainties?. Radiation Oncology, 2016, 11, 139.	2.7	59
110	Usefulness of PET Imaging to Guide Treatment Options in Gliomas. Current Treatment Options in Neurology, 2016, 18, 4.	1.8	16
111	Implementation of the European multicentre database of healthy controls for [123I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1315-1322.	6.4	29
112	Glial Activation and Glucose Metabolism in a Transgenic Amyloid Mouse Model: A Triple-Tracer PET Study. Journal of Nuclear Medicine, 2016, 57, 954-960.	5.0	113
113	Use of PERCIST for Prediction of Progression-Free and Overall Survival After Radioembolization for Liver Metastases from Pancreatic Cancer. Journal of Nuclear Medicine, 2016, 57, 355-360.	5.0	22
114	Early static 18F-FET-PET scans have a higher accuracy for glioma grading than the standard 20â€“40 min scans. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1105-1114.	6.4	88
115	The diagnostic value of [18F]FDG PET for the detection of chronic osteomyelitis and implant-associated infection. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 749-761.	6.4	56
116	Dynamic ¹⁸ F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses. International Journal of Cancer, 2015, 136, 2132-2145.	5.1	68
117	Evaluating Treatment Response of Radioembolization in Intermediate-Stage Hepatocellular Carcinoma Patients Using ¹⁸ F-Fluoroethylcholine PET/CT. Journal of Nuclear Medicine, 2015, 56, 1661-1666.	5.0	28
118	Prognostic Significance of Dynamic ¹⁸ F-FET PET in Newly Diagnosed Astrocytic High-Grade Glioma. Journal of Nuclear Medicine, 2015, 56, 9-15.	5.0	144
119	In-vivo monitoring of erythropoietin treatment after myocardial infarction in mice with [68Ga]Annexin A5 and [18F]FDG PET. Journal of Nuclear Cardiology, 2014, 21, 1191-1199.	2.1	12
120	PET imaging for brain tumor diagnostics. Current Opinion in Neurology, 2014, 27, 683-688.	3.6	32
121	Assessment of cerebral dopamine D2 / 3 -receptors in patients with bilateral vestibular failure. Journal of Vestibular Research: Equilibrium and Orientation, 2014, 24, 403-413.	2.0	12
122	Dynamic ¹⁸ F-FET PET in Newly Diagnosed Astrocytic Low-Grade Glioma Identifies High-Risk Patients. Journal of Nuclear Medicine, 2014, 55, 198-203.	5.0	123
123	[18F]-fluoro-ethyl-l-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro-Oncology, 2013, 15, 341-351.	1.2	192
124	Atypical parkinsonism due to a <i>D202N</i> Gerstmann-Strussler-Scheinker prion protein mutation: First in vivo diagnosed case. Movement Disorders, 2013, 28, 241-245.	3.9	14
125	Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [18F]FET-PET imaging in intracranial WHO grade II and III gliomas. Neuro-Oncology, 2012, 14, 1473-1480.	1.2	91
126	Re-irradiation in recurrent malignant glioma: prognostic value of [18F]FET-PET. Journal of Neuro-Oncology, 2012, 110, 389-395.	2.9	34

#	ARTICLE	IF	CITATIONS
127	Diagnostic role of whole-body [18F]-FDG positron emission tomography in patients with symptoms suspicious for malignancy after heart transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 958-966.	0.6	12